Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025

Stock Information for Windtree Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.